Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.20 (16.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conference presentation

22 Jun 2020 07:00

RNS Number : 5746Q
Physiomics PLC
22 June 2020
 

22 June 2020

 

Physiomics plc

("Physiomics") or ("the Company")

 

Conference presentation

 

Physiomics to present on dual immuno-therapy at AACR 2020 Virtual Meeting II

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research ("AACR") Annual Meeting 2020, being held as a virtual event.

 

The Company will be presenting on a new version of its Virtual Tumour™ model, which is able to simulate the efficacy of dual immuno-therapy regimens. The model was originally developed as part of a client project.

 

The Company will be presenting an original poster in the session "LBPO.IM02 - Late-Breaking Research: Immunology 2", scheduled for 22 June 2020 at 9.00 a.m. - 6.00 p.m. EDT (Eastern Daylight Time). The poster is titled "Optimising dual immuno-oncology combinations with Virtual Tumour" (Abstract # LB-392). The session will include live interactions and the poster will remain available for viewing by registered attendees for at least three months after the virtual meeting.

 

Over recent years, driven by a number of actual client projects, we have extended our Virtual Tumour™ technology from a tool to predict the effect of drugs directly targeting tumour growth inhibition, into one that can also simulate the effects of immuno-therapies. This latest release of the Virtual Tumour™ immune module can simulate the effects of established immune checkpoints (e.g. anti PD-(L)1) in combination with agents targeting components of the innate immune system, such as myeloid derived suppressor cells (e.g. complement inhibitors).

 

A copy of the poster will be made available on Physiomics' website at 9.00 a.m. EDT (2.00 p.m. BST) at: https://www.physiomics.co.uk/resources.

 

According to AACR, it is the oldest and largest scientific organisation in the world, focused on every aspect of high-quality, innovative cancer research. Its annual conference is usually attended by representatives from public and private sector organisations, from the very small to the largest global players, with over 20,000 participants attending in 2019. This year, as a virtual event, access will be free to everyone who registers, and presentations may therefore reach a wider audience than usual.

 

More information about the conference may be found using the following link: https://www.aacr.org/meeting/aacr-annual-meeting-2020.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAGZGZVVMVGGZM
Date   Source Headline
21st Mar 20247:00 amRNSIMC Presentation on Company Website
18th Mar 20247:00 amRNSContract Award
7th Mar 20247:00 amRNSInterim Results
1st Mar 20243:00 pmRNSNotice of Results and Investor Presentation
19th Feb 20247:00 amRNSContract Award
6th Feb 20247:00 amRNSOptions Award
5th Feb 20247:00 amRNSContract Award
2nd Feb 20247:00 amRNSIMC Presentation on Company Website
23rd Jan 20247:00 amRNSIMC Presentation on Board Changes
22nd Jan 20247:00 amRNSBoard Changes
21st Nov 20233:30 pmRNSResult of AGM
10th Nov 20233:14 pmRNSBusiness Update Presentation
10th Nov 20237:00 amRNSInnovate UK grant award
18th Oct 20237:00 amRNSNotice of AGM
4th Oct 20237:00 amRNSChange of Registered Office
3rd Oct 20237:00 amRNSSenior Management Announcement
28th Sep 20237:00 amRNSAnnual Financial Report
4th Sep 20237:00 amRNSSenior Management Update
31st Aug 20231:00 pmRNSContract Award
31st Aug 20237:00 amRNSContract Award
8th Aug 20237:45 amRNSContract Award
4th Aug 20237:00 amRNSContract Award
25th Jul 20237:00 amRNSDirector Dealing
18th Jul 20237:00 amRNSDirector Dealing
29th Jun 20237:00 amRNSCompletion of Placing, Subscription & Retail Offer
27th Jun 20237:01 amRNSWRAP Retail Offer for up to £150,000
27th Jun 20237:00 amRNSCompletion of Equity Fundraise
31st May 20237:00 amRNSCollaboration with The University of Sheffield
23rd May 20237:00 amRNSTrading Update
9th May 20237:00 amRNSPublication of article in Frontiers in Oncology
26th Apr 20237:00 amRNSCollaborative Services Agreement
14th Apr 20237:00 amRNSPhysiomics to present at AACR Annual Meeting
4th Apr 20237:00 amRNSTrading and Company Update
28th Mar 20237:00 amRNSAnnouncement of Collaboration
10th Mar 20237:00 amRNSContract announcement
7th Mar 20237:00 amRNSInterim Results
13th Jan 20237:00 amRNSChange in role of board Director
11th Jan 20237:00 amRNSContract announcement
9th Jan 20237:00 amRNSCompletion of PARTNER study
22nd Nov 20224:00 pmRNSResult of AGM
10th Nov 20228:50 amRNSContract award
9th Nov 20227:00 amRNSPYC to present and exhibit at SITC Annual Meeting
27th Oct 20227:00 amRNSAnnual Report and AGM Notice
14th Oct 20227:00 amRNSConference Attendance
12th Oct 20227:00 amRNSContract Award
4th Oct 20227:00 amRNSContract Award
29th Sep 20227:00 amRNSInterim Results
9th Sep 20227:00 amRNSNotice of Results
1st Sep 20227:00 amRNSAppointment of Independent Non-Executive Director
7th Jul 20227:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.